September 15, 2004

Decoupling the Control of Brain Cancer Cells
to Find Better Treatments

(Philadelphia, PA) - When he’s not in the operating room performing surgery, Donald M. O’Rourke, MD, Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine is fighting brain tumors from the research laboratory bench. He and colleagues are making inroads to understanding the basic molecular biology that makes brain tumors so hard to treat. An estimated 41,000 new cases of primary brain tumors are expected to be diagnosed in 2004, according to the American Brain Tumor Association.

Most recently, O’Rourke and Gurpreet S. Kapoor, PhD, Research Associate in O’Rourke’s laboratory, have discovered that two proteins sitting on the surface of cells are the interconnected switches for turning uncontrolled cell growth on or off in the brain and other tissues. These coupled proteins are the Epidermal Growth Factor Receptor (EGFR) and the Signal Regulatory Proteina1 (SIRPa1). They report their findings in the September 15 issue of Cancer Research.

In past work, O’Rourke and colleagues found that if EGFR was activated, cancer cells tended to survive longer and migrate to unaffected parts of the brain to spread the cancer. In over 50 percent of glioblastomas - one type of brain cancer that is the leading cause of cancer-related deaths in males aged 20-39 - too much EGFR is produced. In other glioblastomas, too much of a variant called EGFRvIII is also produced, which is linked to poor survival and resistance to treatment in some brain-cancer patients.

“Most of my translational efforts are targeted at this variant form of EGFR since no treatments are out there for glioblastomas,” says O’Rourke. “We believe that development of malignancy in the brain is not simply related to cell division; it’s a combined process that involves cell division, cell survival, cell migration and movement, and ultimately angiogenesis - the building of new blood vessels in tumors.” All four of these processes occur at the same time. Many of the conventional chemotherapies for brain tumors are directed at stopping cell division, which makes these therapies not completely successful.

Using human glioblastoma cells, they found that when another protein called SHP-2 is bound to EGFR, the cell goes into an overactive state, resulting in cancerous growth. However, when SHP-2 is bound to SIRPa1, uncontrolled cell growth is stopped. “This is probably the normal state for a brain cell,” says O’Rourke.

O’Rourke showed in earlier work that when SIRPa1 is activated in cancer cells it can inhibit cell growth and eventually kill them. In the present study, though, O’Rourke and Kapoor demonstrate that when EGFR is turned on, the genetic machinery to produce SIRPa1 is shut down, effectively bypassing the cell’s natural ability to control unchecked growth. Another way a cancer cell circumvents the brakes on reproducing is to sequester SHP-2 away from SIRPa1, so the cell keeps on dividing.

Many of the newer cancer therapies inhibit EGFR activation, which is an indirect way of treating cancer. Stimulating SIRPa1 may be a more direct way to stop cancer because that receptor is a naturally occurring way that the body inhibits cancerous growth. “We may then have a greater chance at beating brain cancer than by inhibiting EGFR in a cell that already has an abundance of EGFR in it,” says O’Rourke. Future efforts by O’Rourke’s laboratory will be directed at finding combinations of inhibitors that block brain cancer cell migration, which will make all local therapies - including surgery - more effective by confining the cancer to a particular location.

This research was funded by the National Institutes of Health, the Department of Veterans Affairs, and The Brain Tumor Society.

For a printer friendly version of this release, click here.

###

PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation’s first integrated academic health system).

Penn’s School of Medicine is ranked #3 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report’s most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System is comprised of: its flagship hospital, the Hospital of the University of Pennsylvania, consistently rated one of the nation’s “Honor Roll” hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; Presbyterian Medical Center; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home health care and hospice.